VOLPE, Gisella
 Distribuzione geografica
Continente #
NA - Nord America 790
EU - Europa 350
AS - Asia 197
AF - Africa 1
SA - Sud America 1
Totale 1.339
Nazione #
US - Stati Uniti d'America 780
CN - Cina 111
IT - Italia 58
IE - Irlanda 55
SE - Svezia 41
FI - Finlandia 36
FR - Francia 36
UA - Ucraina 33
DE - Germania 27
KR - Corea 22
SG - Singapore 19
PL - Polonia 18
AT - Austria 17
GB - Regno Unito 15
JP - Giappone 15
VN - Vietnam 13
BE - Belgio 9
CA - Canada 9
HK - Hong Kong 9
IN - India 3
IQ - Iraq 3
TR - Turchia 2
AR - Argentina 1
CZ - Repubblica Ceca 1
EE - Estonia 1
ES - Italia 1
MX - Messico 1
NO - Norvegia 1
RU - Federazione Russa 1
SN - Senegal 1
Totale 1.339
Città #
Chandler 138
Beijing 84
Dublin 55
Fairfield 54
Ann Arbor 43
Ashburn 40
Fremont 31
Houston 29
Woodbridge 29
Villeurbanne 27
Wilmington 27
Cambridge 26
Seattle 26
Nyköping 25
Torino 21
Dearborn 20
Jacksonville 20
Pisa 18
Warsaw 18
Medford 17
Vienna 17
Princeton 16
Dong Ket 13
Falls Church 12
Brussels 9
Hong Kong 9
Singapore 9
Düsseldorf 8
Milan 8
Boardman 6
Boston 5
Nanjing 5
Redmond 4
Toronto 4
Des Moines 3
Hefei 3
Lachine 3
Phoenix 3
Shanghai 3
Washington 3
Arbil 2
Helsinki 2
Honolulu 2
Jinan 2
Kunming 2
Los Angeles 2
Ottawa 2
Redwood City 2
San Diego 2
San Jose 2
Tokyo 2
Upper Marlboro 2
Verona 2
Xian 2
Zhengzhou 2
Akron 1
Antalya 1
Auburn Hills 1
Bengaluru 1
Bogen 1
Borgo San Dalmazzo 1
Brno 1
Changchun 1
Genova 1
Guangzhou 1
Hangzhou 1
Indianapolis 1
La Jolla 1
Meerut 1
Modena 1
Mountain View 1
Munich 1
New York 1
Norwalk 1
Philadelphia 1
Phoenixville 1
Porth 1
Rouen 1
Saint-sulpice-et-cameyrac 1
San Mateo 1
San Nicolas 1
Seoul 1
Shaoxing 1
Shenyang 1
Silver Spring 1
Stavanger 1
Suzhou 1
Takamatsu 1
Tallinn 1
Turin 1
Villar 1
Totale 957
Nome #
Analysis of microsatellite instability in chronic lymphoproliferative disorders 186
New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia 168
The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy 162
NEW ALTERNATIVE PROTEIN Bcr/Abl-OOF SHOWS ONCOGENIC ACTIVITY BY ACTIVATION OF RAC AND COOPERATION WITH Bcr/Abl IN CHRONIC MYELOID LEUKEMIA. 112
Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients 107
Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case report. 103
Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches 90
A new oncogenic role of BCR-ABL/OOF in chronic myeloid leukemia pathogenesis 87
Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice 64
Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients 59
Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia 55
Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice 54
New perspectives for molecular targeted therapy in human leukemias 53
Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteins. 47
Imatinib resistance in CML 42
Totale 1.389
Categoria #
all - tutte 3.872
article - articoli 0
book - libri 0
conference - conferenze 576
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.448


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020211 17 7 10 28 15 28 28 14 18 27 9 10
2020/2021150 12 15 17 5 20 3 11 7 13 10 13 24
2021/2022192 5 7 3 13 11 8 10 12 4 17 67 35
2022/2023320 27 40 7 43 25 79 15 19 35 6 18 6
2023/202489 15 23 6 3 3 7 2 5 0 4 7 14
2024/20252 2 0 0 0 0 0 0 0 0 0 0 0
Totale 1.389